Dicycloplatin

Drug Profile

Dicycloplatin

Alternative Names: DCP

Latest Information Update: 17 Feb 2016

Price : $50

At a glance

  • Originator Peking University
  • Developer Sopo-Xingda Pharmaceutical
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Non-small cell lung cancer

Most Recent Events

  • 16 Feb 2016 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy) in China (IV)
  • 16 Feb 2016 No development reported - Registered for Cancer in China (IV)
  • 23 Oct 2013 Pharmacodynamics data from a Preclinical trial and pharmacokinetics data from a Clinical trial presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top